Merck & Co., Inc. (MRK)
| Market Cap | 205.97B |
| Revenue (ttm) | 49.15B |
| Net Income (ttm) | 7.20B |
| Shares Out | 2.53B |
| EPS (ttm) | 2.83 |
| PE Ratio | 28.77 |
| Forward PE | 10.10 |
| Dividend | $2.61 (3.20%) |
| Ex-Dividend Date | Dec 14, 2021 |
| Volume | 13,854,431 |
| Open | 81.10 |
| Previous Close | 81.38 |
| Day's Range | 80.80 - 82.16 |
| 52-Week Range | 68.44 - 91.40 |
| Beta | 0.50 |
| Analysts | Buy |
| Price Target | 92.50 (+13.4%) |
| Earnings Date | Oct 28, 2021 |
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected ide...
Financial Performance
Financial StatementsAnalyst Forecast
According to 25 analysts, the average rating for Merck & Co. stock is "Buy." The 12-month stock price forecast is 92.50, which is an increase of 13.44% from the latest price.
News
Merck's KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo in Certain Patients Wit...
KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA Significantly Improved Overall Survival (OS) in Patients With Advanced Hepatocellular Carcinoma (HCC) Previously Treated With Sorafenib
Final Trades: Wynn, Goldman Sachs, Merck & more
The "Halftime Report" traders give their top picks to watch for the second half.
Merck Animal Health's Third Veterinarian Wellbeing Study Reveals Increased Health Challenges and Psychological Distre...
MADISON, N.J., Jan. 18, 2022 /PRNewswire/ -- Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Kenilworth, N.J.
Merck and Ridgeback Biotherapeutics to supply 3 million doses of COVID antiviral to Unicef in 2022
Merck MRK, +0.07% and partner privately held Ridgeback Biotherapeutics said Tuesday they have won a supply agreement from the United Nations Children's Fund, or Unicef, to provide it with up to 3 millio...
Merck and Ridgeback Announce Supply Agreement with UNICEF for Molnupiravir, an Investigational Oral Antiviral COVID-1...
KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)---- $MRK #MRK--Merck and Ridgeback Announce Supply Agreement with UNICEF for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine
4 Large-Cap Drugmaker Stocks to Watch Despite Omicron Woes
Drug/biotech and medical device companies are likely to remain in the spotlight in 2022. Among the large drugmakers Roche (RHHBY), Pfizer (PFE), AbbVie (ABBV), and Merck (MRK) are worth retaining in you...
How Do Pfizer's and Merck's COVID Pills Work?
The two oral COVID-19 therapies use completely different mechanisms to fight the coronavirus.
2 Top Healthcare Stocks to Buy Right Now
Don't wait too long to buy shares of these two companies.
Merck Snags Yet Another Indication for This Drug Combo
The company's blockbuster cancer drug Keytruda was approved in Japan to treat patients with certain types of endometrial cancer.
Merck (MRK) Stock Sinks As Market Gains: What You Should Know
Merck (MRK) closed the most recent trading day at $81.20, moving -0.58% from the previous trading session.
Omicron-specific vaccines are ‘already priced into COVID stocks': Jefferies Managing Director
Jefferies Managing Director Michael Yee joins Yahoo Finance Live's Julie Hyman and Brian Sozzi to discuss the biotech sector, outlook for M&A activity, and the outlook for COVID-19 stocks.
Merck (MRK) Keytruda Betters Survival in Adjuvant Lung Cancer
Merck's (MRK) phase III study evaluating Keytruda for adjuvant stage IB-IIIA non-small cell lung cancer (NSCLC) meets one of its dual primary endpoints of disease-free survival (DFS).
Gilead (GILD) Partners With Merck for Keytruda in NSCLC Study
Gilead (GILD) and Merck collaborate to evaluate the former's breast cancer drug in combination with the latter's blockbuster drug Keytruda for NSCLC study.
Here's A Better Pharmaceutical Pick Over Merck Stock
We think that Bristol Myers Squibb stock (NYSE: BMY) currently is a better pick compared to its industry peer, Merck stock (NYSE: MRK), given its better growth prospects and comparatively lower valuatio...
Final Trades: Goldman Sachs, Abbvie, Merck & more
The "Halftime Report" traders give their top picks to watch for the second half.
Absci (ABSI) Inks Research Agreement With Merck, Stock Up
Absci (ABSI) signs a deal with Merck for using its AI-powered drug creation platform to produce enzymes for Merck's biomanufacturing applications with an option for the development of three novel drugs.
Merck's Keytruda As Adjuvant Treatment Improves Disease-Free Survival In Lung Cancer Setting
Merck & Co Inc (NYSE: MRK) has announced that the Phase 3 KEYNOTE-091 trial, investigating Keytruda, met one of its dual primary endpoints in NSCLC patients following surgical resection regardless of PD...
Merck's KEYTRUDA® (pembrolizumab) Showed Statistically Significant Improvement in Disease-Free Survival Versus Placeb...
KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA Showed Significant Improvement in Disease-Free Survival as Adjuvant Treatment for Stage IB-IIIA NSCLC Regardless of PD-L1 Expression
3 Big FDA Approvals to Watch For in Q1 2022
Some of the world's biggest drugmakers have important dates with the FDA coming up soon.
Merck to Hold Fourth-Quarter and Full-Year 2021 Sales and Earnings Conference Call on February 3
KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Hold Fourth-Quarter and Full-Year 2021 Sales and Earnings Conference Call on February 3
Absci Corp up 50% after announcing research collaboration with Merck
Absci Corporation (NASDAQ: ABSI) went up 50% after it announced that it had executed a research and collaboration agreement with Merck, commonly referred to as MSD outside Canada and the US. The company...
3 Dow Stocks to Buy Hand Over Fist in January
These Dow stocks provide investors with safe and growing payouts at reasonable valuations.
Market Recap Wednesday, January 5: Stocks close at lows
Technology stocks came under renewed pressure on Wednesday while the Dow Jones Industrial Average pulled back from a fresh record high. Darrell Cronk, Wells Fargo CIO of Wealth & Investment Management a...